Current Opinion in Lipidology volume 28, issue 6, P452-457 2017 DOI: 10.1097/mol.0000000000000456 View full text
|
|
Share
Klaus G. Parhofer

Abstract: Some of the new lipid-lowering drugs have a very promising profile. However, eventually phase 3 and outcome trials will be required to prove the usefulness of these compounds in clinical practice. Furthermore, it is unlikely that they will change the primary lipidological approach (statin and ezetimibe) even if they prove successful.